bis(diphenyl-2-pyridylphosphine)palladium(II) dichloride | 78088-45-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: bis(diphenyl-2-pyridylphosphine)palladium(II) dichloride
• 英文别名: Pd(2-diphenylphosphinopyridine)2Cl2；[Pd(κ1-2-pyridyldiphenylphosphine)2Cl2]；[PdCl2(2-[diphenylphosphino]pyridine)2]；cis-{PdCl2(PPh2py-P)2}；[cis-Pd(κ1-2-pyridyldiphenylphosphine)2Cl2]；{bis(diphenylphosphino)-2-pyridyl}palladium(II) chloride；trans-{PdCl2(PPh2py-P)2}；[trans-Pd(κ1-2-pyridyldiphenylphosphine)2Cl2]
• CAS: 78088-45-6；38255-46-8；84773-43-3；1246525-11-0
• 化学式: C₃₄H₂₈Cl₂N₂P₂Pd
• 分子量: 703.883
• InChiKey: UUAZREQOLWKPBV-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  None
• 重原子数：
  None
• 可旋转键数：
  None
• 环数：
  None
• sp3杂化的碳原子比例：
  None
• 拓扑面积：
  None
• 氢给体数：
  None
• 氢受体数：
  None

文献信息

• (Perfluoro)alkylsilyl-Substituted 2-[Bis(4-aryl)phosphino]pyridines:  Synthesis and Comparison of Their Palladium Complexes in Methoxycarbonylation of Phenylacetylene in Regular Solvents and Supercritical CO₂
  作者：Jeroen. J. M. de Pater、C. Elizabeth P. Maljaars、Elwin de Wolf、Martin Lutz、Anthony L. Spek、Berth-Jan Deelman、Cornelis J. Elsevier、Gerard van Koten

  DOI：10.1021/om050479+

  日期：2005.10.1

  derived from [Pd(OAc)2] as the palladium source with either 9 or 10 as ligand showed the same activity (TON = 4000, 50 min reaction time) and selectivity (about 98% for the branched product) as the catalyst obtained from [Pd(OAc)2] and 2-[diphenylphosphino]pyridine (2). Both 2 and 10 were also tested in this reaction using a 1:1 mixture of methanol and α,α‘,α‘ ‘-trifluorotoluene as solvent system:  fluorous

  三种新的2- [双4-（溴）苯基}膦基]吡啶（8），2- [双4-（三甲基甲硅烷基）苯基}膦基]吡啶（9）和2- [双报道了4-（（2-（全氟己基乙基）乙基）二甲基甲硅烷基）苯基}膦基]吡啶（10）配体（L）。相应的化合物的反式- /顺- [的PdCl 2（L）2 ] 11 - 13，反式- [的PdCl（ME）（L）2 ] 14 - 16，和马来酸酐配合物[加入Pd（L）2（环- （ -CH CHC（O）OC（O）-）] 17和合成并表征了18种。在甲醇中苯乙炔的甲氧基羰基化反应中，衍生自[Pd（OAc）2 ]作为钯源的钯或9或10配体表现出相同的活性（TON = 4000，反应时间为50分钟）和选择性（对于Pd（OAc）2为50％，选择性约为98％）。由[Pd（OAc）2 ]和2- [二苯基膦基]吡啶（2）获得的作为催化剂的支链产物）。既2和10也被在此反应中，使用1测试：甲醇和
• Synthesis and Characterization of Palladium(II) and Platinum(II) Complexes Containing Monodentate Phosphorus Donating or Chelating 2-(Dimethylphosphino)pyridine (PMe₂py)
  作者：Takayoshi Suzuki、Masakazu Kita、Kazuo Kashiwabara、Junnosuke Fujita

  DOI：10.1246/bcsj.63.3434

  日期：1990.12

  The complexes [MX2(PMe2py-P)2] (M=Pd(II), Pt(II); X=Cl, Br, and I) have been synthesized and characterized both in the solid state and in solution by their infrared and 1H, 13C, and 31P NMR spectra, in addition to an X-ray crystallographic analysis of cis-[PdCl2(PMe2py-P)2]. The latter complex exists as a cis–trans equilibrium mixture in solution, while only the cis isomer has been isolated in the

  复合物 [MX2(PMe2py-P)2] (M=Pd(II), Pt(II); X=Cl, Br, and I) 已被合成并在固态和溶液中通过它们的红外和除了顺式-[PdCl2(PMe2py-P)2] 的 X 射线晶体学分析外，还有 1H、13C 和 31P NMR 光谱。后一种复合物在溶液中以顺反平衡混合物的形式存在，而只有顺式异构体在固态下被分离出来。[PdBr2(PMe2py-P)2] 络合物作为反式异构体被分离出来，在溶液中也表现出相同的异构化，而 [PdBr2(PMe2Ph)2] 仅作为反式异构体以固态和在解决方案中。此外，已发现 PMe2py 具有通过氮和磷原子螯合形成四元螯合环的能力。络合物中的螯合环 [PdX(PMe2py)2]Y (X=Cl, Br, and I; Y=ClO4-, PF6-) 已通过 cis(P,P)-[PdCl(PMe2py-P,N)(PMe2py-P)]
• Activity of phosphino palladium(II) and platinum(II) complexes against HIV-1 and Mycobacterium tuberculosis
  作者：Ntombenhle H. Gama、Afag Y. F. Elkhadir、Bhavna G. Gordhan、Bavesh D. Kana、James Darkwa、Debra Meyer

  DOI：10.1007/s10534-016-9940-6

  日期：2016.8

  coinfection. Bis(diphenylphosphino)-2-pyridylpalladium(II) chloride (1), bis(diphenylphosphino)-2-pyridylplatinum(II) chloride (2), bis(diphenylphosphino)-2-ethylpyridylpalladium(II) chloride (3) and bis(diphenylphosphino)-2-ethylpyridylplatinum(II) (4) were investigated for the inhibition of HIV-1 through interactions with the viral protease. The complexes were subsequently assessed for biological potency

  目前，由于结核分枝杆菌的合并感染患病率增加，人类免疫缺陷病毒（HIV）的治疗变得复杂。同时提供艾滋病毒和结核病（TB）治疗的候选药物的开发将对艾滋病毒/艾滋病的整体治疗产生巨大的好处，特别是在全球艾滋病毒/艾滋病合并感染率最高的撒哈拉以南非洲地区。双（二苯基膦基）-2-吡啶基氯化钯（II）（1），双（二苯基膦基）-2-吡啶基氯化铂（II）（2），双（二苯基膦基）-2-乙基吡啶基氯化钯（II）和双（研究了二苯基膦基-2-乙基吡啶基铂（II）（4）通过与病毒蛋白酶相互作用抑制HIV-1的作用。随后通过使用肉汤微量稀释确定最小抑制浓度（MIC）来评估复合物对结核分枝杆菌H37Rv的生物效价。复合物（3）显示出对HIV-1蛋白酶的最显着和竞争性抑制作用（在100 µM，p = 0.014）。对其体外对全病毒的影响的进一步研究表明，在63 µM时，病毒的感染性降低了80％以上（p <0.05）。此外，该复合物在MIC为5
• The synthesis of, and characterization of the dynamic processes occurring in Pd(ii) chelate complexes of 2-pyridyldiphenylphosphine
  作者：Jianke Liu、Chacko Jacob、Kelly J. Sheridan、Firas Al-Mosule、Brian T. Heaton、Jonathan A. Iggo、Mark Matthews、Jeremie Pelletier、Robin Whyman、Jamie F. Bickley、Alexander Steiner

  DOI：10.1039/b918162h

  日期：——

  Pd(II) complexes in which 2-pyridyldiphenylphosphine (Ph2Ppy) chelates the Pd(II) centre have been prepared and characterized by multinuclear NMR spectroscopy and by X-ray crystallographic analysis. trans-[Pd(κ1-Ph2Ppy)2Cl2] is transformed into [Pd(κ2-Ph2Ppy)(κ1-Ph2Ppy)Cl]Cl by the addition of a few drops of methanol to dichloromethane solutions, and into [Pd(κ2-Ph2Ppy)(κ1-Ph2Ppy)Cl]X by addition of AgX or TlX, (X = BF4−, CF3SO3− or MeSO3−). [Pd(κ1-Ph2Ppy)2(p-benzoquinone)] can be transformed into [Pd(κ2-Ph2Ppy)(κ1-Ph2Ppy)(MeSO3)][MeSO3] by the addition of two equivalents of MeSO3H. Addition of further MeSO3H affords [Pd(κ2-Ph2Ppy)(κ1-Ph2PpyH)(MeSO3)][MeSO3]2. Addition of two equivalents of CF3SO3H, MeSO3H or CF3CO2H and two equivalents of Ph2Ppy to [Pd(OAc)2] in CH2Cl2 or CH2Cl2–MeOH affords [Pd(κ2-Ph2Ppy)(κ1-Ph2Ppy)X]X, (X = CF3SO3−, MeSO3− or CF3CO2−), however addition of two equivalents of HBF4·Et2O affords a different complex, tentatively formulated as [Pd(κ2-Ph2Ppy)2]X2. Addition of excess acid results in the clean formation of [Pd(κ2-Ph2Ppy)(κ1-Ph2PpyH)(X)]X2. In methanol, addition of MeSO3H and three equivalents of Ph2Ppy to [Pd(OAc)2] affords [Pd(κ2-Ph2Ppy)(κ1-Ph2Ppy)2][MeSO3]2 as the principal Pd-phosphine complex. The fluxional processes occuring in these complexes and in [Pd (κ1-Ph2Ppy)3Cl]X, (X = Cl, OTf) and the potential for hemilability of the Ph2Ppy ligand has been investigated by variable-temperature NMR. The activation entropy and enthalpy for the regiospecific fluxional processes occuring in [Pd(κ2-Ph2Ppy)(κ1-Ph2Ppy)2][MeSO3]2 have been determined and are in the range −10 to −30 J mol−1 K−1 and ca. 30 kJ mol−1 respectively, consistent with associative pathways being followed. The observed regioselectivities of the exchanges are attributed to the constraints imposed by microscopic reversibility and the small bite angle of the Ph2Ppy ligand. X-Ray crystal structure determinations of trans-[Pd(κ1-Ph2Ppy)2Cl2], [Pd(κ2-Ph2Ppy)(κ1-Ph2Ppy)Cl][BF4], [Pd(κ1-Ph2Ppy)2(p-benzoquinone)], trans-[Pd(κ1-Ph2PpyH)2Cl2][MeSO3]2, and [Pd(κ1-Ph2Ppy)3Cl](Cl) are reported. In [Pd(κ2-Ph2Ppy)(κ1-Ph2Ppy)Cl][BF4] a donor–acceptor interaction is seen between the pyridyl-N of the monodentate Ph2Ppy ligand and the phosphorus of the chelating Ph2Ppy resulting in a trigonal bipyramidal geometry at this phosphorus.

  制备了 2-吡啶二苯基膦 (Ph2Ppy) 螯合 Pd(II) 中心的 Pd(II) 配合物，并通过多核 NMR 光谱和 X 射线晶体分析对其进行了表征。通过向二氯甲烷溶液中添加几滴甲醇，反式-[Pd(κ1-Ph2Ppy)2Cl2]转化为[Pd(κ2-Ph2Ppy)(κ1-Ph2Ppy)Cl]Cl，并转化为[Pd(κ2-Ph2Ppy) )(κ1-Ph2Ppy)Cl]X 通过添加 AgX 或 TlX，（X = BF4−、CF3SO3− 或 MeSO3−）。通过添加两当量的 MeSO3H，[Pd(κ1-Ph2Ppy)2(对苯醌)]可以转化为 [Pd(κ2-Ph2Ppy)(κ1-Ph2Ppy)(MeSO3)][MeSO3]。进一步添加 MeSO3H 得到 [Pd(κ2-Ph2Ppy)(κ1-Ph2PpyH)(MeSO3)][MeSO3]2。将两当量的 CF3SO3H、MeSO3H 或 CF3CO2H 和两当量的 Ph2Ppy 添加到 CH2Cl2 或 –MeOH 中的 [Pd(OAc)2] 中，得到 [Pd(κ2-Ph2Ppy)(κ1-Ph2Ppy)X]X，(X = CF3SO3 -、MeSO3- 或 CF3CO2-），但是添加两当量的 H ·Et2O 会得到不同的复合物，暂定为 [Pd(κ2-Ph2Ppy)2]X2。添加过量的酸导致 [Pd(κ2-Ph2Ppy)(κ1-Ph2PpyH)(X)]X2 的干净形成。在甲醇中，将 MeSO3H 和三当量的 Ph2Ppy 添加到 [Pd(OAc)2] 中，得到 [Pd(κ2-Ph2Ppy)(κ1-Ph2Ppy)2][MeSO3]2 作为主要的 Pd-膦络合物。这些配合物和 [Pd (κ1-Ph2Ppy)3Cl]X (X = Cl, OTf) 中发生的通量过程以及 Ph2Ppy 配体的半稳定性的潜力已通过变温 NMR 进行了研究。 [Pd(κ2-Ph2Ppy)(κ1-Ph2Ppy)2][MeSO3]2 中发生的区域特异性通量过程的活化熵和焓已确定，范围为 -10 至 -30 J mol−1 K−1和约。分别为 30 kJ mol−1，与所遵循的关联路径一致。观察到的交换区域选择性归因于微观可逆性和 Ph2Ppy 配体的小咬角所施加的限制。反式-[Pd(κ1-Ph2Ppy)2Cl2]、[Pd(κ2-Ph2Ppy)(κ1-Ph2Ppy)Cl][ ]、[Pd(κ1-Ph2Ppy)2(对苯醌)的X射线晶体结构测定]、反式-[Pd(κ1-Ph2PpyH)2Cl2][MeSO3]2 和 [Pd(κ1-Ph2Ppy)3Cl](Cl) 已报道。在 [Pd(κ2-Ph2Ppy)(κ1-Ph2Ppy)Cl][ ] 中，单齿 Ph2Ppy 配体的吡啶基-N 和螯合 Ph2Ppy 的磷之间存在供体-受体相互作用，从而形成三角双锥几何形状。磷。
• Synthesis, Physicochemical Characterization, Biological Evaluation, In Silico and Molecular Docking Studies of Pd(II) Complexes with P, S-Donor Ligands
  作者：Hizbullah Khan、Muhammad Sirajuddin、Amin Badshah、Sajjad Ahmad、Muhammad Bilal、Syed Muhammad Salman、Ian S. Butler、Tanveer A. Wani、Seema Zargar

  DOI：10.3390/ph16060806

  日期：——

  One homoleptic (1) and three heteroleptic (2–4) palladium(II) complexes were synthesized and characterized by various physicochemical techniques, i.e., elemental analysis, FTIR, Raman spectroscopy, 1H, 13C, and 31P NMR. Compound 1 was also confirmed by single crystal XRD, showing a slightly distorted square planar geometry. The antibacterial results obtained via the agar-well diffusion method for compound 1 were maximum among the screen compounds. All the compounds have shown good to significant antibacterial results against the tested bacterial strains, Escherichia coli, Klebsiella pneumonia, and Staphylococcus aureus, except 2 against Klebsiella pneumonia. Similarly, the molecular docking study of compound 3 has shown the best affinity with binding energy scores of −8.6569, −6.5716, and −7.6966 kcal/mol against Escherichia coli, Klebsiella pneumonia, and Staphylococcus aureus, respectively. Compound 2 has exhibited the highest activity (3.67 µM), followed by compound 3 (4.57 µM), 1 (6.94 µM), and 4 (21.7 µM) against the DU145 human prostate cancer cell line using the sulforhodamine B (SRB) method as compared to cisplatin (>200 µM). The highest docking score was obtained for compounds 2 (−7.5148 kcal/mol) and 3 (−7.0343 kcal/mol). Compound 2 shows that the Cl atom of the compound acts as a chain side acceptor for the DR5 receptor residue Asp B218 and the pyridine ring is involved in interaction with the Tyr A50 residue via arene-H, while Compound 3 interacts with the Asp B218 residue via the Cl atom. The physicochemical parameters determined by the SwissADME webserver revealed that no blood-brain barrier (BBB) permeation is predicted for all four compounds, while gastrointestinal absorption is low for compound 1 and high for the rest of the compounds (2–4). As concluding remarks based on the obtained in vitro biological results, the evaluated compounds after in vivo studies might be a good choice for future antibiotics and anticancer agents.

  通过各种理化技术，即元素分析、傅里叶变换红外光谱、拉曼光谱、1H、13C 和 31P NMR，合成了一种同象（1）和三种异象（2-4）钯（II）配合物，并对其进行了表征。化合物 1 还通过单晶 XRD 得到了证实，显示出略微扭曲的方形平面几何形状。化合物 1 通过琼脂-孔扩散法获得的抗菌结果是所有筛选化合物中最高的。除了 2 号化合物对肺炎克雷伯氏菌的抗菌效果较好外，其他化合物对大肠埃希菌、肺炎克雷伯氏菌和金黄色葡萄球菌等细菌菌株都有良好或显著的抗菌效果。同样，化合物 3 的分子对接研究显示其亲和力最佳，对大肠埃希菌、肺炎克雷伯菌和金黄色葡萄球菌的结合能得分分别为 -8.6569、-6.5716 和 -7.6966 kcal/mol。与顺铂 (>200 µM)相比，化合物 2 采用磺基罗丹明 B (SRB) 法对 DU145 人类前列腺癌细胞系的活性最高（3.67 µM），其次是化合物 3 (4.57 µM)、1 (6.94 µM) 和 4 (21.7 µM)。化合物 2（-7.5148 kcal/mol）和化合物 3（-7.0343 kcal/mol）的对接得分最高。化合物 2 表明该化合物的 Cl 原子作为 DR5 受体残基 Asp B218 的链侧受体，吡啶环通过炔-H 与 Tyr A50 残基相互作用，而化合物 3 则通过 Cl 原子与 Asp B218 残基相互作用。通过 SwissADME 网络服务器测定的理化参数显示，预计所有四种化合物都不会通过血脑屏障（BBB），而化合物 1 的胃肠道吸收率较低，其余化合物的胃肠道吸收率较高（2-4）。最后，根据所获得的体外生物学结果，经过体内研究后，所评估的化合物可能是未来抗生素和抗癌剂的良好选择。